Optimizing primary chemotherapy in ovarian cancer

Hematology/Oncology Clinics of North America

Volumn 17, Issue 4, 2003, Pages 957-968

  Markman, Maurie ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; PACLITAXEL;

ACUTE LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; NEUROTOXICITY; NEUTROPENIA; OVARY CARCINOMA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0042433487     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(03)00058-3     Document Type: Review

References (50)

1. Kottmeier HL. Treatment of ovarian cancer with thiotepa. Clin Obstet Gynecol 1968;11:428-38.
2. Thigpen T, Vance R, Lambuth B, Balducci L, Khansur T, Blessing J, et al. Chemotherapy for advanced or recurrent gynecologic cancer. Cancer 1987;60:2104-16.
3. Katz ME, Schwartz PE, Kapp DS, Luikart S. Epithelial carcinoma of the ovary: current strategies. Ann Intern Med 1981;95:98-111.
4. Young RC, Chabner BA, Hubbard SP, Fisher RI, Bender RA, Anderson T, et al. Advanced ovarian adenocarcinoma: a prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med 1978;299:1261-6.
5. Cannistra SA. Cancer of the ovary. N Engl J Med 1993;329:1550-9.
6. Advanced Ovarian Cancer Trialists' Group, Aabo K, Adams M, Adnitt P, Alberts DS, Athanazziou A, Barley V, et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Br J Cancer 1998;78(11):1479-87.
7. Alberts DS, Green S, Hannigan EV, O'Toole R, Stock-Novack D, Anderson P, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992;10:706-17.
8. Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G, Carmichael J, et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials group. J Clin Oncol 1992;10:718-26.
9. Lambert HE, Rustin GJS, Gregory WM, Nelstrop AE. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma: a North Thames Ovary Group study. Ann Oncol 1997;8:327-33.
10. Bertelsen K, Jakobsen A, Stroyer I, Nielsen K, Sandberg E, Andersen JE, et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Gynecol Oncol 1993;49:30-6.
11. Hakes TB, Chalas E, Hoskins WJ, Jones WB, Markman M, Rubin SC, et al. Randomized prospective trial of five versus ten cycles of cyclophosphamide, doxorubicin and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 1992;45:284-9.
12. McGuire WP, Hoskins WJ, Brady MF, Homesley HD, Creasman WT, Berman ML, et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 1995;13:1589-99.
13. Gore M, Mainwaring P, A'Hern R, MacFarlane V, Slevin M, Harper P, et al. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. J Clin Oncol 1998;16:2426-34.
14. Jakobsen A, Bertelsen K, Andersen JE, Havsteen H, Jakobsen P, Moeller KA, et al. Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. J Clin Oncol 1997;15:193-8.
15. Repetto L, Pace M, Mammoliti S, Bruzzone M, Chiara S, Oliva C, et al. The impact of received dose intensity on the outcome of advanced ovarian cancer. Eur J Cancer 1993;29A:181-4.
16. Wrigley E, Weaver A, Jayson G, Ranson M, Renninson J, Prendiville J, et al. A randomised trial investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma: a comparison of chemotherapy given every four weeks with the same chemotherapy given at three week intervals. Ann Oncol 1996;7:705-11.
17. Conte PF, Bruzzone M, Carnino F, Gadducci A, Algeri R, Bellini A, et al. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. J Clin Oncol 1996;14:351-6.
18. Joly F, Heron JF, Kerbrat P, Chauvergne J, Rios M, Mayer F, et al. High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC). Gynecol Oncol 2000;78:361-8.
19. Kaye SB, Lewis CR, Paul J, Duncan ID, Gordon HK, Kitchener HC, et al. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 1992;340:329-33.
20. Kaye SB, Paul J, Cassidy J, Lewis CR, Duncan ID, Gordon HK, et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. J Clin Oncol 1996;14:2113-9.
21. Aghajanian C, Fennelly D, Shapiro F, Waltzman R, Almadrones L, O'Flaherty C, et al. Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer. J Clin Oncol 1998;16:1852-60.
22. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL, van Oosterom AT, Willemse PHB, Heintz APM, et al. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol 1987;5:1157-68.
23. Ovarian Cancer Meta-Analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. J Clin Oncol 1991;9:1668-74.
24. A'Hern RP, Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 1995;13:726-32.
25. Fanning J, Bennett TZ, Hilgers RD. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma. Obstet Gynecol 1992;80:954-60.
26. The ICON Collaborators. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. Lancet 1998;352:1571-6.
27. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989;111:273-9.
28. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 1994;12:1748-53.
29. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
30. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699-708.
31. Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2000;18:106-15.
32. The Intemational Collaborative Ovarian Neoplasm (ICON) Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002;360:505-15.
33. Connelly E, Markman M, Kennedy A, Webster K, Kulp B, Peterson G, et al. Paclitaxel delivered as a 3-hour infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. Gynecol Oncol 1996;62:166-8.
34. Ozols RF, Bundy BN, Fowler J, Clarke-Pearson D, Mannel R, Hartenbach EM, et al. Randomized phase III study of cisplatin(CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 158) [abstract 1373]. In: Proceedings of the American Society of Clinical Oncology; 1999. p. 356a.
35. du Bois A, Lueck HJ, Meier W, Moebus V, Costa SD, Bauknecht T, et al. Cisplatin/paclitaxel vs. carboplatin/paclitaxel in ovarian cancer: update of an Arbeitgemeinschaft Gynaekologische Onkologie (AGO) Study Group trial [abstact 1374]. In: Proceedings of the American Society of Clinical Oncology; 1999. p. 356a.
36. Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000;18:3084-92.
37. Francis P, Schneider J, Hann L, Balmaceda C, Barakat R, Phillips M, et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 1994;12:2301-8.
38. Verschraegen CF, Sittisomwong T, Kudelka AP, de Paula Guedes E, Steger M, Nelson-Taylor T, et al. Docetaxel for patients with paclitaxel-resistant mullerian carcinoma. J Clin Oncol 2000;18:2733-9.
39. Vasey P, on behalf of the Scottish Gynaecologic Cancer Trials Group. Preliminary results of the SCOTROC trial: a phase III comparison of paclitaxel-carboplatin (PC) and docetaxel-carboplatin (DC) as first-line chemotherapy for stage Ic-IV epithelial ovarian cancer (EOC) [abstract 804]. In: Proceedings of the American Society of Clinical Oncology; 2001. p. 202a.
40. Vasey PA, on behalf of the Scottish Gynaecological Cancer Trials Group. Survival and longer-term toxicity results of the SCOTROC study: docetaxel-carboplatin (DC) vs. paclitaxel-carboplatin (PC) in epithelial ovarian cancer (EOC) [abstract 804]. In: Proceedings of the American Society of Clinical Oncology; 2002. p. 202a.
41. Markman M. Intraperitoneal chemotherapy. Crit Rev Oncol/Hematol 1999;31:239-46.
42. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950-5.
43. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:1001-7.
44. Armstrong DK, Bundy BN, Baergen R, Lele SB, Copeland LJ, Walker J, et al. Randomized phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG I72) [abstract 803]. In: Proceedings of the American Society of Clinical Oncology; 2002 p. 201a.
45. Markman M, Hakes T, Barakat R, Curtin J, Almadrones L, Hoskins W. Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center Protocol 9103: paclitaxel in refractory ovarian cancer. J Clin Oncol 1996;14:796-9.
46. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-86.
47. Markman M, Liu PY, Wilczynski S, Monk BJ, Copeland L, Alberts D. Phase 3 randomized trial of 12 versus 3 months of single-agent paclitaxel in patients with advanced ovarian cancer who attained a clinically defined complete response to platinum/paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003; in press.
48. Vergote IB, Trimbos BJ, Guthrie D, Parmar M, Bolis G, Mangioni C, et al. Results of a randomized trial in 923 patients with high-risk early ovarian cancer, comparing adjuvant chemotherapy with no further treatment following surgery [abstract 802]. In: Proceedings of the American Society of Clinical Oncology; 2001. p. 201a.
49. Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist 2000;5:26-35.
50. Lavarino C, Pilotti S, Oggionni M, Gatti L, Perego P, Bresciani G, et al. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 2000;18:3936-45.